

539,447

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/057340 A1

(51) International Patent Classification⁷: G01N 33/68

(21) International Application Number:
PCT/GB2003/005595

(22) International Filing Date:
22 December 2003 (22.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/435,349 23 December 2002 (23.12.2002) US
0230172.9 24 December 2002 (24.12.2002) GB

(71) Applicant (*for all designated States except US*): ASTEX TECHNOLOGY LIMITED [GB/GB]; 436 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0QA (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): JHOTI, Harren [GB/GB]; c/o Astex Technology Limited, 436 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0QA (GB). CONGREVE, Miles, Stuart [GB/GB]; c/o Astex Technology Limited, 436 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0QA (GB). O'REILLY, Marc [GB/GB]; c/o Astex Technology Limited, 436 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0QA (GB). WYATT,

Paul, Graham [GB/GB]; c/o Astex Technology Limited, 436 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire CB4 0QA (GB).

(74) Agents: WATSON, Robert, J. et al.; Mewburn Ellis, York House, 23 Kingsway, London, Greater London WC2B 6HP (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/057340 A1

(54) Title: SYNTHESIS AND SCREENING OF LIGANDS USING X-RAY CRYSTALLOGRAPHY

(57) Abstract: A method for identifying a ligand of a target macromolecule is disclosed, comprising the steps of: soaking one or more crystals of the target macromolecule in a solution containing a collection of compounds generated in situ or separate from the crystal, where the solution has been prepared without the purification of the synthesized collection of compounds; obtaining an X-ray crystal diffraction pattern of the soaked macromolecule crystal; and using said X-ray crystal diffraction pattern to identify any compound bound to the macromolecule crystal, said compound being a ligand of the target macromolecule.

SYNTHESIS AND SCREENING OF LIGANDS USING X-RAY CRYSTALLOGRAPHY

This invention relates to methods for synthesising compounds and identifying from those compounds ligands that bind target
5 macromolecules using X-ray crystallography.

Background

Determining the structure of proteins by X-ray crystallography is an elegant and reliable method and is the basis of structure-
10 based ligand design in which small molecules are synthesized as potential ligands for the protein of interest. This is an intense area of research for the optimisation of ligands to drugs for therapeutically interesting proteins (see Babine, R.E. and Bender, S.L., *Chemical Reviews*, 97, 1359-1472 (1997) and Bohacek,
15 R.S., et al., *Med. Res. Rev.*, 16, 3-50 (1996)).

One method of ligand screening is described in WO 99/45379, in which a library of shape-diverse compounds thought to be potential ligands are soaked or co-crystallised with a target
20 protein, and then the resulting complex is analysed by X-ray crystallography to determine the nature of the ligand which has bound. The library of compounds which is used in the screening process generally comprises previously characterised compounds.

25 Summary of the Invention

The above described method requires every potential ligand to be synthesized, purified and characterized before it can form part of a library for screening. If the potential ligands are simply purchased from commercial sources, their costs will typically be
30 high due to the amount of work required to carry out these three steps. If, in the alternative, the compounds are to be synthesized 'in-house', then a great deal of time and effort will need to be expended on assembling the library of ligands for screening.

35

The present inventors have developed a method where a collection of compounds is synthesized and then screened without the need

- 2 -

for any purification and/or characterisation steps.

Accordingly, the present invention provides a method for identifying a ligand of a target macromolecule comprising the
5 steps of:

- a) soaking one or more crystals of the target macromolecule in a solution containing a collection of compounds generated in situ or separate from the crystal, where the solution has been prepared without the purification, and preferably without the characterisation, of the synthesized collection of compounds;
- b) obtaining an X-ray crystal diffraction pattern of the soaked macromolecule crystal; and
- c) using said X-ray crystal diffraction pattern to identify any compound bound to the macromolecule crystal, said compound being a ligand of the target macromolecule.

Any solvated crystal system in which the solvent and/or ligand molecules are able to infiltrate throughout the crystal via
20 diffusion, and where the crystal system is compatible with X-ray diffraction data collection, is suitable for use in the invention.

Examples of appropriate macromolecules are polypeptides
25 (proteins), ribose nucleic acids (RNAs, ribozymes etc), deoxy ribose nucleic acids (DNAs), and complexes of combinations of the three examples, e.g. ribosomes, or viruses (DNA and/or RNA-protein complexes).

30 A ligand is a molecule which can bind to a macromolecule. For a polypeptide chain (protein), this is anything that is not coded for by the DNA sequence of the protein. This covers the post-translational modification of proteins (e.g. covalent attachment of sugars, etc.), the covalent and non-covalent attachment of
35 cofactors (e.g. Haem groups), the binding of other polypeptides or amino acids, the binding of small molecules (e.g. drugs, substrates, etc.) and the binding of DNA and RNA to proteins. For

- 3 -

nucleic acids this is molecules either covalently, or non-covalently bound to DNA or RNA (e.g. ligands intercalated between bases).

- 5 In the present invention, the compounds can be synthesised by parallel synthesis, or (more conveniently) by combinatorial chemistry. Traditionally, combinatorial chemistry is used to generate small molecule inhibitors for screening against one or more biological targets. The synthesis of libraries of compounds
10 has generally been aimed at producing either compounds as purified single entities or as high-quality mixtures of compounds using methodology that allows for deconvolution of the mixture, once it has been determined that an active compound is to be found in that mixture. Deconvolution requires the re-testing of
15 each member compound of the active library. Thus either method requires the careful analysis and characterisation of the libraries to allow for interpretation of the data generated during biological screening against the target macromolecule. As mentioned above, the present invention does not require the
20 purification and/or characterisation of the members of the synthesised library, as the identity of the ligand is determined by X-ray crystallography of the ligand-macromolecule complex.
- 25 The solution containing the collection of compounds can be prepared in two main ways, herein called 'in-situ' synthesis and 'just-in-time' synthesis.
30 'In-situ' synthesis involves synthesizing the collection of compounds in a solution which also contains the one or more crystals of the target macromolecule, and therefore requires the use of chemistries which can be carried out under conditions in which the macromolecule crystal will remain stable.
- 35 Accordingly, a first aspect of the present invention provides a method for identifying a ligand of a target macromolecule comprising the steps of:

- 4 -

- a) synthesizing a collection of compounds, which are suitable for screening against a target macromolecule, in a solution containing one or more crystals of the target macromolecule;
- 5 b) obtaining an X-ray crystal diffraction pattern of the soaked macromolecule crystal; and
- c) using said X-ray crystal diffraction pattern to identify any compound bound to the macromolecule crystal, said compound being a ligand of the target macromolecule.

10

In this method, the synthesis of the collection of compounds will take place in a single reaction vessel, i.e. the vessel in which the solution containing one or more crystals of the target macromolecule is present.

15

'Just-in-time' synthesis involves synthesizing the collection of compounds remotely from the solution which contains the one or more crystals of the target protein, and then transferring the synthesized collection into the solution containing the one or 20 more crystals of the target protein. No purification and/or characterisation of the synthesized collection is carried out. The synthesis may take place in a solvent which is not compatible with the macromolecule crystals, from which the collection of compounds must be separated in order to add them to the solution 25 containing the macromolecule crystals.

Accordingly, a second aspect of the present invention provides a method for identifying a ligand of a target macromolecule comprising the steps of:

- 20 a) synthesizing a collection of unpurified compounds suitable for screening against a target macromolecule
- b) adding the collection of compounds to a solution containing one or more crystals of the target macromolecule;
- 35 c) obtaining an X-ray crystal diffraction pattern of the soaked macromolecule crystal; and
- d) using said X-ray crystal diffraction pattern to identify

- 5 -

any compound bound to the macromolecule crystal, said compound being a ligand of the target macromolecule.

In this method, the synthesis of the collection of unpurified
5 compounds may occur in one or more reaction vessels.

If step a) takes place in a solvent which is not compatible with
the macromolecule crystals then after step a) the collection of
compounds is separated from the solvent in which the compounds
10 were synthesised.

Typically, such non-compatible solvents are organic and the step
of separating the collection of compounds from this solvent is
usually carried out by evaporating the solvent. This is then
15 followed by re-dissolution of the collection of compounds in the
solution containing the one or more macromolecule crystals.

Enzyme catalysis in organic solvents has attracted much interest
in recent years (Mattos C. and Ringe D., *Curr Opin Struct
20 Biol.*, 11(6), 761-4) and the use of enzymes in non-aqueous media
has extended the field of biocatalysis (*ASGSB Bull.*, 4(2), 125-132
(1991)). Much work has been done to map out organic binding sites
in crystals by soaking the crystals in organic solvents (English,
A.C., et al., *Proteins*, 37, 628-640 (1999); Mattos C. and Ringe
25 D., Nauret *Biotechnol.*, 14(5), 595-9 (1996)). In addition it has
been shown that enzyme crystals can retain activity in organic
solvents, both in the presence and absence of crosslinking agents
(Ayala, M., et al., *Biochem. Biophys. Res. Comm.*, 295(4), 828-31
9 (2002)).

30

An alternative approach is to separate the non-compatible solvent
from the solution containing the one or more macromolecule
crystals by a permeable membrane, which allows transfer of the
compounds in the collection from the non-compatible solvent to
35 the solution containing the one or more macromolecule crystals.
This approach requires a membrane which is porous enough to allow
the diffusion of the synthesised compounds from the solvent in

- 6 -

which they were synthesised to the solution containing the one or more macromolecules, whilst substantially preventing any diffusion of the solvents. Dialysis buttons provide one means by which this can occur, and are available, for example, from

- 5 Hampton Research. Their use is described in 'Crystallisation of Nucleic Acids and Proteins, edited by Ducruix, A. and Giege, R., The Practical Approach Series, Oxford University Press, 1992.

- The ligands identified by the methods of the present invention
10 may be subsequently modified to alter their binding to the target macromolecule or to improve their usefulness as a pharmaceutical.

Such modification is conventional in the art. Possible modifications include: substitution or removal of groups containing residues which interact with the target macromolecule,
15 for example groups which interact with the amino acid side chain groups of a protein; the addition or removal of groups in order to decrease or increase the charge of a group in a compound; the replacement of a charge group with a group of the opposite charge; or the replacement of a hydrophobic group with a
20 hydrophilic group or vice versa. Additionally, a group may be replaced with another retaining similar properties but that better occupies the cavity in the macromolecule increasing the surface of the ligand in contact with the macromolecule cavity. This may be achieved using the methodologies disclosed in this
25 invention, or by conventional synthetic approaches typically utilised by those skilled in the art of medicinal chemistry. Many of these changes will improve the usefulness of a compounds as a pharmaceutical. It will be understood that these are only examples of the type of substitutions considered by medicinal
30 chemists in the development of new pharmaceutical compounds and other modifications may be made, depending upon the nature of the starting compound and its activity.

Without wishing to be bound by theory, the detection of the
35 ligand bound to the target macromolecule relies on the occupancy in the macromolecule crystals of one of the highest affinity ligands, this being driven by ligand-macromolecule interactions.

- 7 -

This method avoids disadvantages associated with biological screening methods in which the alteration of macromolecule activity by a potential ligand is assessed, as in that case compounds which bind weakly but non-specifically can alter macromolecule activity in a non-selective manner. Such non-selective inhibition produces false-positives, as the assay shows protein activity inhibition, but the compound would perform no useful function as a drug, as it would interfere with the activity of other proteins. Only compounds bound in a binding site will be detected by the present method. In particular, only compounds bound in a binding site with resolvable occupancy will be detected by the present method.

15

Binding sites are sites within a macromolecule, or on its surface, at which ligands can bind. Examples are the catalytic or active site of an enzyme (the site on an enzyme at which the amino acid residues involved in catalysing the enzymatic reaction are located), allosteric binding sites (ligand binding sites distinct from the catalytic site, but which can modulate enzymatic activity upon ligand binding), cofactor binding sites (sites involved in binding/co-ordinating cofactors e.g. metal ions), or substrate binding sites (the ligand binding sites on a protein at which the substrates for the enzymatic reaction bind). There are also sites of protein-protein interaction. If the macromolecule is a nucleic acid, then binding sites may be the bases of the nucleic acid, or spaces in their structures, e.g. the major or minor grooves in the helical DNA, interactions with phosphate, ribose or deoxy ribose groups or intercalated between the bases.

The present method also enables screening where the target macromolecule has more than one active site, as the data for each site can be analysed independently from the other sites to determine the compound bound in that site. In such cases, the information the method of the invention provides on the binding

- 8 -

of two or more separate ligands to the target macromolecule can be used in the linked-fragment approach to drug design, in a similar manner to the method described by Greer, et al., *J. Med. Chem.*, 37(8), 1035-1054 (1994) for the synthesis of a thymidylate synthase inhibitor series. The basic concept behind linked-fragment approaches to drug design is to determine (computationally or experimentally) the binding location of plural ligands to a target molecule, and then to construct a molecular scaffold to connect the ligands together in such a way that their relative binding positions is preserved. The methods of synthesis and screening of the present invention may then be used to determine the best ligands from a library of such compounds, or individual compounds binding ability can be assessed using known methods.

15

Even if the present invention only provides information on the binding of ligands at a single binding site of a target macromolecule, a structure-based approach can be used to develop ligands which interact with further binding sites. Such a fragment growing approach is described in Blundell, T., et al., *Nature Reviews Drug Discovery*, vol. 11, 45-54 (2002).

It is preferred that the members of the collection of compounds are present at a concentration of at least 5 to 50 times, typically at least 10, their K_i (depending case by case with the macromolecule used) so that the occupation of the binding site in the target macromolecule will not depend on the relative quantities of each compound in the collection.

30 In the case of competitive binding of a ligand to a macromolecule K_i is defined as:

$$K_i = \frac{[M][L]}{[ML]}$$

where $[M]$ is the concentration of the macromolecule, $[L]$ is the concentration of free ligand, $[ML]$ is the concentration of the ligand-macromolecule complex.

- 9 -

Where inhibitors are binding in an uncompetitive or non-competitive fashion the K_i is defined as in Fundamentals of Enzyme Kinetics by A. Cornish-Bowden, Portland Press, 1995, ISBN 1 85579 0720, which is herein incorporated by reference.

5

It is preferred that the amount of each compound, being a member of the collection of compounds, present in the solution will be present at a concentration which is at least 5 or 10 times as much as the concentration of the target macromolecule in the 10 reaction system, more preferably 100, 1 000 or even 10 000 times the concentration of the target macromolecule in the reaction system.

The binding of the ligands to the target macromolecule may be 15 through non-covalent interactions or covalent bonding. If the target macromolecule is a protein, then covalent binding of the ligand to the protein may occur when the active site of the protein contains a catalytic residue such as in serine and cysteine proteases. If the target macromolecule is a nucleic acid, then certain classes of compounds are known to interact by 20 covalent binding, e.g. pyrrolobenzodiazepines covalently bind to the exocyclic amino group of guanine.

In some embodiments of the present invention, it is preferred 25 that the members of the collection of compounds do not bind covalently to the target macromolecule, but that they interact through non-covalent binding.

Further aspects of the invention relate to any novel compounds 30 disclosed herein, their use as pharmaceuticals and their use in methods of therapy. In particular, further aspects of the invention include:

- a) a ligand identified by the method of the present invention, or salts, solvates and chemically protected forms thereof;
- 35 b) a pharmaceutical composition comprising a ligand identified by the method of the present invention, or salts, solvates and chemically protected forms thereof, and a pharmaceutically

- 10 -

acceptable carrier or diluent;

c) the use of a ligand identified by the method of the present invention, or salts, solvates and protected forms thereof, in a method of treatment of the human or animal body;

5 d) the use of a ligand identified by the method of the present invention, or salts, solvates and protected forms thereof, in the manufacture of a medicament for the treatment of a disease ameliorated by the binding of a ligand to the target macromolecule used in the method of the invention; and

10 e) a method for the treatment of a disease ameliorated by the binding of a ligand to the target macromolecule used in the method of the invention comprising administering to a subject suffering from said disease a therapeutically-effective amount of a ligand identified by the method of the present invention, or
15 salts and solvates.

Suitable carriers and diluents and information on pharmaceutical compositions can be found in standard pharmaceutical texts, for example, *Handbook of Pharmaceutical Additives*, 2nd Edition (eds.

20 M. Ash and I. Ash), 2001 (Synapse Information Resources, Inc., Endicott, New York, USA); *Remington's Pharmaceutical Sciences*, 20th Edition, pub. Lippincott, Williams & Wilkins, 2000; and *Handbook of Pharmaceutical Excipients*, 2nd edition, 1994.

25 Further details of the invention will now be presented by way of explanation and example.

Although the discussion below focuses on the purification, crystal growth, X-ray crystallography and determination of ligand
30 structure when the macromolecule is a protein, the techniques described are, in general, applicable to other macromolecules, such as nucleic acids and complexes, with appropriate modifications as known to the person skilled in the art.

35 Target Protein Purification.

A specific target protein can be isolated from animal, plant, or bacterial sources directly, or via recombinant methods. The

- 11 -

generation of recombinant protein, using systems such as insect cells (e.g. *S. frugiperda*, or *Drosophila* cells), *E. coli*, yeast (*S. cerevisiae*, *S. pombe*, *P. Pastoris*, etc) or modified human cell lines, means that truncated, or otherwise genetically

5 engineered, proteins can be generated. A protein crystallography project to obtain crystals normally necessitates access to a recombinant protein production system, but the method of the present invention may be performed with a single crystal, which may constitute, for example, between 0.1 and 100 µg.

10

It is generally accepted that the higher the degree of purity and homogeneity of a protein preparation the easier that it will be to grow protein crystals from the preparation. Protein purity reflects the number of protein species within a preparation. It

15 also refers to the number, and nature, of any other non-protein species present (e.g. low molecular weight contaminants). An ideal protein preparation should contain solely one protein species, or one species of protein complex, in which all the protein molecules, or protein complexes, are identical in terms

20 of their amino acid composition, mass etc. The purity of a protein preparation may be gauged via a variety of experimental techniques such as sodium dodecyl sulphate page (SDS-page) gels, mass spectrometry, antibody binding and detection (Western blotting), etc.. Protein purities in excess of 90% are often

25 deemed acceptable for crystallisation trials, but practitioners of the art of protein purification will generally try and strive for purities in excess of this arbitrary threshold, due to the perceived benefits of maximising protein purities.

30 Within a protein preparation, homogeneity can refer to the degree of uniformity observed for parameters such as the stoichiometry of proteins in a multiprotein complex, the mono-dispersity of the protein/complexes in solution, the oxidation, or protonation,

35 state of amino-acid side chains, within proteins, the uniformity of post translational modifications (e.g. are all protein molecules within the population equivalently phosphorolated, glycosylated, or have any essential co-factors been uniformly and

- 12 -

correctly incorporated) and the protein conformations that exist within a given population of protein molecules/complexes. The homogeneity of a protein preparation may be probed using a multitude of experimental methods some of which are: mass-
5 spectrometry, Western blotting, SDS-page, analytical ultracentrifugation, size-exclusion chromatography, affinity chromatography, ion-exchange chromatography, hydrophobic interaction chromatography, surface plasmon resonance, activity assay, electron microscopy, dynamic light scattering (DLS), N-
10 terminal sequencing, iso-electric focussing (IEF), proteolytic digest, fluorescence, circular dichroism (CD), native gel electrophoresis, bandshift assays, or nuclear magnetic resonance (NMR). Maximising the degree of homogeneity within a protein preparation is again deemed desirable, as maximising homogeneity
15 is also believed to positively correlate with maximising crystallisability.

The Growth of Protein Crystals

Crystallisation of any species requires the formation of a
20 supersaturated solution of the species in question and a nucleation event that is capable of initiating crystal growth. Post-nucleation the ambient conditions must be such that crystal growth can be sustained until the physical dimensions and properties of the crystals thus obtained are adequate for any
25 subsequent experimental procedures required. Protein molecules typically only retain their structural integrity within an aqueous environment. Therefore protein crystals are normally grown in the aqueous phase. Protein crystals may grow if a nucleation event occurs in a pure and homogeneous protein
30 solution that has been driven to a state of super-saturation.

Protein crystallisation is generally attempted using the vapour diffusion (sitting drop, hanging drop, sandwich drop, pH gradient etc), dialysis, batch, micro-batch, liquid-liquid diffusion, or
35 in-gel-crystallisation methods. All these methodologies have been extensively described (Protein Crystallisation: Techniques, Strategies and Tips, Edited by T.M. Bergfors, IUL Biotechnology

- 13 -

Series, 1999, Published by International University Line, La Jolla, California, ISBN: 0-9636817-5-3). All of the aforementioned crystallisation processes function by generating a supersaturated protein solution, which promotes the spontaneous
5 formation of crystallisation nuclei, and which is then subsequently able to sustain crystal growth.

There are diverse physico-chemical parameters that can influence whether or not a protein construct, or protein complex, will

10 crystallise. Typically each protein crystallizes under a unique set of conditions, which cannot be predicted in advance. Simply driving the protein concentration to super-saturation, to bring it out of solution, will generally not work. The result would, in most cases, be an amorphous precipitate. Some parameters that

15 may be varied are: the pH of solutions, the choice and concentration of buffer (if any) (e.g. Phosphate, MES, BIS-TRIS, TRIS, BES, PIPES, HEPES, MOPS, BICINE, CHES, CAPS etc), temperature, choice of crystallisation method (see above), volume of crystallisation, protein concentration, the addition of

20 reducing agents (e.g. DTT, β-mercaptoethanol), detergents (e.g. decyl-β-D-maltoside, dodecyl-β-D-maltoside, ocytl-β-D-glucopyranoside, decanoyl-N-methylglucamide, Triton, octyltetraoxyethylene ether, etc.), alcohols (e.g. ethanol, isopropanol, methanol, 2-methyl-2,4-pentanediol (MPD)), salts

25 (e.g. chlorides, acetates, sulphates, phosphates, bromides, iodides, fluorides, nitrates, bicarbonates, chlorates, chromates, citrates, tartrates, cacodylates, formates, hydroxides, etc.), polyethylene glycols (PEGS), ethylene glycols, methoxy polyethylene glycols (MPEGS), heavy atoms and ions (e.g. iron,

30 copper, zinc, cobalt, manganese, nickel, tungstates, vanadates, sodium, magnesium, potassium, lithium, calcium, aluminium, Xenon, etc.), or other additives such as dimethylsulfoxide (DMSO), denaturants (e.g. urea, guanadinium chloride, etc.), glycerol, sulfabetaines, jeffamines, AMPPNP, ATP, ADP, GTP, GDP peptides,

35 tertiary-butanol, amino acids, azides, DNAs, RNAs, sugars, lipids, drugs, etc..

- 14 -

There are numerous crystallisation kits available (e.g. from Hampton Research), which attempt to broadly sample as many parameters in crystallization space as possible. In many cases these general screens help to identify a starting point for

- 5 crystallisations in the form of crystalline precipitates and/or rough, or micro-, crystals. Typically these crystals are unsuitable for direct diffraction analysis and require further optimisation. Successful crystallization can be aided by knowledge of a protein's behaviour in terms of solubility,
10 dependence on metal ions for correct folding or activity, interactions with other molecules and any other data that are available.

Systematically screening such a large number of parameters
15 represents an extremely complex multi-dimensional search problem and is, as such, exceptionally difficult to perform in a systematic manner. Even with the advent of automated protein crystallisation it is often the case that crystallisation of a protein will require a very high degree of human input and the
20 impact of intangible parameters such as serendipity, insight, and random error.

If preliminary crystals have been obtained it is often necessary to further modify the crystallisation conditions in an attempt to
25 simultaneously maximise the internal order and physical dimensions of the crystals grown. Optimising these parameters is deemed beneficial for helping to maximise the data quality obtained in subsequent X-ray diffraction experiments.
Identification of a set of initial crystallisation conditions
30 reduces the potential parameter space that has to be explored, but crystal optimisation can still remain a time consuming and laborious process. Techniques such as macro- or micro-seeding may also aid crystal optimisation.

35 Details of some of the proteins crystallised, and information on some of the protein crystallisation conditions identified, are contained, for example, within the following internet databases:

- 15 -

<http://wwwbmcd.nist.gov:8080/bmcd/bmcd.html> (Gilliland, G.L., et al., *Acta Crystallogr.*, **D50**, 408-413 (1994));

<http://xray.bmc.uu.se/embo/structdb/links.html>;

[http://www.mpibp-](http://www.mpibp-frankfurt.mpg.de/michel/public/memprotstruct.html)

5 [frankfurt.mpg.de/michel/public/memprotstruct.html;](http://www.rcsb.org/pdb/)

<http://www.rcsb.org/pdb/> (Berman, H.M., et al., *Nucleic Acids Research*, **28**, 235-242 (2000));

<http://www.ebi.ac.uk/msd/>

and have been described in the following publications:

10 Blundell, T., et al., "Protein Crystallography", Academic Press, New York (1976); McPherson, et al., "Preparation and Analysis of Protein Crystals" in "Preparation and Analysis of Protein Crystals", John Wiley & Sons, New York (1982); Carter, et al., "Design of crystallization experiments and protocols.",

15 pages 47-71 in "Crystallization of Nucleic Acids and Proteins - A Practical Approach", (Ducruix, A. & Giege, R., eds) IRL Press, Oxford (1992); Ducruix, A., et al., "Methods of crystallization.", pages 73-98 in "Crystallization of Nucleic Acids and Proteins - A Practical Approach", (Ducruix, A. & Giege, R., eds) IRL Press, Oxford (1992); "Protein Crystallisation: techniques, strategies, and tips." IUL Biotechnology Series (1999), ISBN 0-9636817-5-3.

Obtaining X-ray diffraction data from soaked protein crystals

25 An X-ray diffraction experiment consists of exposing a protein crystal to a collimated, coherent, beam of X-rays and recording the resulting X-ray diffraction pattern. A diffraction pattern arises from the elastic scatter of X-rays off electrons within the planes of atoms within a protein crystal. The mathematics underlying X-ray diffraction may be represented in their simplest form by the Bragg equation:

$$n\lambda=2ds\sin\theta$$

where n is an integer, λ is the wavelength of the incident X-rays, θ is the scattering angle of the X-rays off a given plane

35 of atoms, and d is the Bragg spacing, or spacing between successive planes of atoms (Bragg planes). Thus as long as λ corresponds to atomic scales (i.e. $\approx 1\text{\AA}$) then atomic scale

- 16 -

features should be discernable within an electron density map calculated using the diffraction data. Typically it is considered that X-ray data are required to a Bragg spacing of $\leq 3 \text{ \AA}$, for a given X-ray wavelength, if the data from an X-ray diffraction experiment are to be of use in determining the atomic positions within a structure. During an experiment the various Bragg planes within a crystal will only satisfy the mathematical criteria necessary for diffraction at specific crystal orientations relative to the incident X-ray beam. So as to obtain diffraction data relating to as many Bragg planes as possible the crystal is rotated in the X-ray beam. Thus all possible plane orientations are explored. The angle through which a crystal must be rotated in order to obtain a complete set of data relating to a specific Bragg spacing is defined by the space group of the crystal and also the initial orientation of the crystal in the X-ray beam. The smallest Bragg spacing for which diffraction data are available is termed the resolution of the experiment. It is desirable to maximise the data completeness for an experiment. That is, data should ideally be 100% complete up to the resolution limit of the experiment.

Unfortunately the high energy of X-ray photons means that they cause damage to protein molecules. This is thought to be at least partially due to the generation of ions and free radicals within the crystals. Prolonged exposure of a protein containing crystal to an X-ray beam will thus result in a deterioration and decay of the proteins. This is typically manifested by a decline in the data resolution and quality. This problem may be partially circumvented by cryogenically freezing protein containing crystals in vitreous ice at 100K. Freezing of the crystal means that any ion, or free radical, species that are generated are unable to migrate through the crystal. Thus the longevity of the crystal in the X-ray beam is extended and the data quality and resolution typically improved relative to an unfrozen data collection. Normally protein containing crystals cannot be directly frozen in the solutions in which they grew (mother liquor). This is because direct freezing often leads to

- 17 -

- the formation of ice crystals within the mother liquor. These ice crystals can destroy the internal order within a protein crystal and thus abolish diffraction. The addition of a cryo-protectant to the protein's mother liquor can, however, lead to
- 5 the formation of vitreous ice on freezing. This should not destroy the internal order of a protein crystal and thus retain diffraction from the crystal. Normally protein containing crystals must be transferred from their mother liquor into a specially formulated cryo-protectant solution prior to freezing.
- 10 The exact composition of the cryo-protectant solution, the transfer protocol, and the freezing protocol must be uniquely determined for each crystal system and often for each experiment.

Determination of ligand structure

- 15 A mathematical operation termed a Fourier transform relates the diffraction pattern observed from a crystal and the molecular structure of the protein and ligand comprising the crystal (Blundell, T., et al., "Protein Crystallography", Academic Press, New York (1976); Drenth, "Principles of Protein X-ray
- 20 Crystallography", Springer (1994)). A Fourier transform may be considered to be a summation of sine and cosine waves each with a defined amplitude and phase. Thus, in theory, it is possible to calculate the electron density associated with a protein and ligand structure by carrying out an inverse Fourier transform on
- 25 the diffraction data. This requires amplitude and phase information to be extracted from the diffraction data. Amplitude information may be obtained by analysing the intensities of the spots within a diffraction pattern. The conventional methods for recording diffraction data do, however, mean that any "phase
- 30 information" is lost. This phase information must be in some way recovered and the loss of this information represents the "crystallographic phase problem". The phase information necessary for carrying out the inverse Fourier transform can be obtained via a variety of methods.

35

If the structure of the unsoaked protein is already available, as would normally be the case, a set of theoretical amplitudes and

- 18 -

phases may be calculated using the protein model and then the theoretical phases combined with the experimentally derived amplitudes. An electron density map may then be calculated and the protein and ligand structure observed. Electron density maps
5 can be calculated using programs such as those contained in the CCP4 computing suite (Collaborative Computational Project 4, *Acta Crystallographica, D50*, 760-763 (1994)). For map visualization and model building programs such as "O" (Jones, et al., *Acta Crystallographica, A47*, 110-119 (1991)) or "QUANTA" (Jones, et
10 al., (1991) and commercially available from Accelrys, San Diego, California) can be used.

An alternative approach employs (i) X-ray crystallographic diffraction data from the complex of ligand and protein and (ii)
15 a three-dimensional structure of the unsoaked protein, to generate a difference Fourier electron density map of the complex. The difference Fourier electron density map may then be analysed to identify the ligand.

20 Analysis of electron density maps may be aided by software, for example, AutoSolve® (Blundell, T., et al., *Nature Reviews Drug Discovery*, 11, 45-54 (2002)) or the ligand fitting module in QUANTA, XLIGAND (QUANTA: see above; X-LIGAND: Oldfield, T.J.,
25 *Acta Crystallogr D Biol Crystallogr.*, 57(5), 696-705 (2001)).

If there is no known structure of the protein then alternative methods for obtaining phases must be explored so as to resolve the structure of the unsoaked protein (Blundell, T., et al., "Protein Crystallography", Academic Press, New York (1976)). One
30 method is multiple isomorphous replacement (MIR). This relies on soaking "heavy atom" (i.e. Platinum, Uranium, Mercury, etc) compounds into the crystals and observing how their incorporation into the crystals modifies the spot intensities observed in the diffraction pattern. An alternative method for obtaining phase
35 information for a protein of unknown structure is to perform a multi-wavelength anomalous dispersion (MAD) experiment. This relies on the absorption of X-rays by electrons at certain

- 19 -

characteristic X-ray wavelengths. Anomalous scattering by atoms within a protein will modify the diffraction pattern obtained from the protein crystal. Thus if a protein contains atoms which are capable of anomalous scattering a diffraction dataset 5 (anomalous dataset) may be collected at an X-ray wavelength at which this anomalous scattering is maximal. The most usual way to introduce anomalous scatterers into a protein is to replace the sulphur containing methionine amino acid residues with selenium containing seleno-methionine residues. This is done by 10 generating recombinant protein that is isolated from cells grown in controlled growth media that contains seleno-methionine (Doublie, S., *Methods in Enzymology*, 276, 523-530 (1997)). Selenium is capable of anomalously scattering X-rays and may thus be used for a MAD experiment. Another method generally available 15 for the calculation of the phases necessary for the determination of an unknown protein structure is molecular replacement. This method relies upon the assumption that proteins with similar amino acid sequences (primary sequences) will have a similar fold and three-dimensional structure (tertiary structure). Examples 20 of computer programs known in the art for performing molecular replacement are CNX (Brunger, A.T., et al., *Current Opinion in Structural Biology*, 8(5), 606-611 (1998) and also commercially available from Accelrys San Diego, CA) or AMORE (Navaza, J., *Acta Cryst.*, A50, 157-163 (1994)). The phase information 25 obtained by one of these means, when combined with the experimentally obtained amplitudes from the native dataset, enables an electron density map of the unknown protein molecule to be calculated using the Fourier transform method.

30 If an electron density map has been calculated for a protein of unknown structure then the amino acids comprising the protein must be fitted into the electron density for the protein. This is normally done manually, although high resolution data may enable automatic model building. The process of model building 35 and fitting the amino acids to the electron density can be both a time consuming and laborious process. Once the amino acids have been fitted to the electron density it is necessary to refine the

- 20 -

structure. Refinement attempts to maximise the correlation between the experimentally calculated electron density and the electron density calculated from the protein model built (Blundell, T., et al., "Protein Crystallography", Academic Press,

5 New York (1976) and "Methods in Enzymology", vols. 114 & 115, Wyckoff, H.W., et al., eds., Academic Press (1985)). Refinement also attempts to optimise the geometry and disposition of the atoms and amino acids within the user-constructed model of the protein structure. Sometimes manual re-building of the structure
10 will be required to release the structure from local energetic minima. There are now several software packages available that enable an experimentalist to carry out refinement of a protein structure such as CNX (see above), or REFMAC (Murshudov, G.N., et al., *Acta Crystallographica*, D53, 240-255 (1997)). There are
15 certain geometry and correlation diagnostics that are used to monitor the progress of a refinement. These diagnostic parameters are monitored and rebuilding/refinement continued until the experimenter is satisfied that the structure has been adequately refined.

20

The atomic coordinate data of the co-complexes formed from the methods of the invention can be routinely accessed using computer programs, for example, RASMOL (Sayle, et al., *TIBS*, 20, 374 (1995)), which is a publicly available computer software package,
25 which allows access and analysis of atomic coordinate data for structure determination and/or rational drug design or AstexViewer™ which is contained in the CCP4 computing suite.

Information from X-ray crystallography

30 The information obtained by the method according to the invention can be used to provide much more information than the identity of the ligand which has bound. As the information on the ligand results from fitting to the electron density measured in the protein active site, this can allow the mode of binding and
35 interactions to be ascertained, which can be useful in further elaboration and optimisation of the ligand.

- 21 -

The collections of compounds

The collection of compounds for use in the present invention are produced by one or more synthetic processes designed to connect two or more sets of monomers together. Monomers are molecules

5 which share a common reactivity that makes them capable of combining with another complementary monomer to form a larger compound. Each set of monomers will contain at least one monomer and preferably no more than 100 monomers, such that between about 5 and about 1000 compounds are in each collection of compounds.

10 It is preferred that all the compounds in a collection comprise a common functional group (sometimes referred to as a 'templating moiety') which is produced by the reaction of two or more complimentary functional groups present on the monomer sets used in the synthetic process. In one preferred embodiment each

15 compound in a collection is related to other members of the collection by virtue of being synthesised from at least one common monomer unit. By having common features or trends in the structures of the compounds in the collection, it makes it possible to identify which moieties in the compounds (derived

20 from individual monomer units) bind best to the target protein, even if the independent monomer itself does not have any detectable binding. This is achieved by observing the preference for binding that the macromolecule exhibits for compounds from the collection.

25

It is further preferred that the collection of compounds will have shape features that differ sufficiently to allow at least one set of monomers used in their production to be distinguished from each other. This then allows determination of the chemical

30 structure of the bound ligand, or to at least determine part of its structure. If only part of its structure can be determined, re-synthesis of some of the members of the collection of compound that contain this partial structure will be necessary and these compounds are soaked into the crystal as singlet experiments so

35 that the chemical structure of the bound ligand or ligands can be determined. This type of re-synthesis approach is termed a chemical deconvolution and is well known to practitioners of

- 22 -

combinatorial or parallel synthesis to identify the biologically active member from a mixture of synthesised compounds.

'In-situ' synthesis

- 5 As mentioned above, protein crystals are sensitive to the media in which they are grown and kept, and therefore the methods chosen for 'in-situ' synthesis, i.e. synthesis of the collection of compounds in the presence of the target protein crystals, have to be chosen such that they can occur under conditions which will
10 not destroy the target protein crystal. If some degradation of the crystals occur, this should not be to such an extent that the X-ray diffraction results are not of sufficient quality to allow for identification of the ligand (see above).
- 15 Typically reactions are those which can be carried out in a purely aqueous media at around room temperature (4 to 30°C), and at a pH of 4 to 10.

Examples of these chemistries, which apply to both methods of
20 combinatorial synthesis and parallel synthesis, include:
Acetal or Ketal formation; Addition reactions; Aldol condensations and related condensation reactions; Allylations; Cycloaddition reactions; Disulfide formation; Hydrazone formation; Mannich reactions; Michael reactions and related
25 Conjugate Addition reactions; Palladium mediated reactions; Reductive alkylation; Substitution reactions; and Three or Four Component Reactions.

The following reactions can be carried out using synthetic
30 procedures described in general organic chemistry texts such as March's Advanced Organic Chemistry (Smith, M.B. and March, J., 5th edition, Wiley-Interscience, New York, 2001) or references given therein. Some synthetic reactions carried out in aqueous conditions have recently been reviewed by Ulf Lindstroem, see
35 "Stereoselective Organic Reactions in Water", *Chemical Reviews*, 102(8), 2751-2771 (2002). The practice of combinatorial chemistry is described in references cited in publications by Roland Dolle

- 23 -

(*Journal of Combinatorial Chemistry*, 4(5), 369-418 (2002); *Journal of Combinatorial Chemistry*, 3(6), 477-517 (2001); *Journal of Combinatorial Chemistry*, 2(5), 383-433 (2000); *Molecular Diversity*, 4(4), 233-256 (2000); *Journal of Combinatorial Chemistry*, 1(4), 235-282 (1999); *Molecular Diversity*, 3(4), 199-233 (1998)).


These reactions take place between appropriate sets of ligand precursor molecules ('monomers'), which are represented

10 schematically below, with M representing a substituent group that is varied in each monomer set (e.g. M₁, M₂, M₃, etc.). Each reacting set of monomers can have as few as a single member, up to, for example, 40 members, although a maximum of about 20 members would be more usual. In some embodiments of the invention
 15 it is preferred that each set of reacting monomers comprises at least two monomers. A typical size for the resulting collection of compounds would be between 5 and 1000, preferably between 5 and 100, with a range 10 or 20 to 50 or 70 being preferred.

20 In the following examples, R represents a substituent or H on a monomer.

Acetal or Ketal formation

25 Addition of alcohols or a diol to an aldehyde or ketone, catalysed by acid. The reactions are fully reversible leading to thermodynamic products.





Addition reactions

30 For example, addition to an epoxide under acidic conditions, or

- 24 -

addition of alcohols to enol ethers.




X = O, S, N or P, and where the ring may be optionally substituted on any available position.

5

Aldol condensations and related condensation reactions

For examples, see Kobayashi, S. and Manabe, K., *Accounts of Chemical Research*, 35(4), 209-217 (2002).

10



15

Related condensation reactions are the Knoevenagel reaction, the Peterson reaction, the Perkin reaction, the Darzen's reaction, Tollens' reaction, the Wittig reaction and the Thorpe reaction. Careful selection of the monomers is required in order for these reactions to proceed under aqueous conditions.

Allylations


For examples, see Kobayashi, S. and Hachiya, I., *Yuki Gosei Kagaku Kyokaishi*, 53(5), 370-80 (1995).

20

Cycloaddition reactions

For example, the Diels-Alder reaction, see Fringuelli, F., et al., *European Journal of Organic Chemistry*, 3, 439-455 (2001).

- 25 -




Many variations exist of the above formula, including where heteroatoms are incorporated (e.g. aza-Diels-Alder reactions).

- 5 Cycloadditions to form 5 membered ring systems are also very general and an illustrative example is the cycloaddition of nitrile oxides with alkynes to form oxazoles which occurs at room temperature under very mild conditions.




- 10 An example of a cycloaddition reaction that is water-tolerant is the "click chemistry" described by Sharpless in Lewis, et al., *Angew. Chem. Int. Ed.*, **41**(6), 1053-1057 (2002). In this an azide and an acetylene undergo a Huisgen 1,3-dipolar cycloaddition to give 1,2,3-triazoles.

15



Disulfide formation

Occurs reversibly under very mild conditions.



20

- 26 -


Hydrazone formation

Occurs reversibly under very mild conditions.




5 *Mannich reactions*

For examples, see Akiyama, T., et al., *Advanced Synthesis & Catalysis*, 344(3+4), 338-347 (2002).



10 *Michael reactions and related Conjugate Addition reactions*

Addition of nucleophiles to α,β -unsaturated carbonyl compounds is another example of addition reactions suitable for use in the invention.



15 The carbonyl can also be replaced by other electron withdrawing groups, such as nitro groups, see Da Silva, F. and Jones, J., *Journal of the Brazilian Chemical Society*, 12(2), 135-137 (2001).


A related transformation is the Baylis Hillman reaction, see Yu, C., et al., *Journal of Organic Chemistry*, 66(16), 5413-5418 (2001).

Palladium mediated reactions

Many palladium mediated reactions can be carried out in aqueous media, e.g. Heck, Sonogashira, Tsuji-Trost, Suzuki, Stille, see

- 27 -


Pierre Genet, J. and Savignac, M., *Journal of Organometallic Chemistry*, 576(1-2), 305-317 (1999). A representative illustration is the Suzuki cross coupling reaction:



5

Reductive alkylation

Occurs under very mild conditions. An example carried out in the presence of a protein is Hochguertel, M., et al., *Proceedings of the National Academy of Sciences of the United States of America*, 99(6), 3382-3387 (2002).



Substitution reactions

Many useful substitution reactions occur under aqueous conditions, e.g. nucleophilic displacement (with alcohols, amines, thiols, carboxylic acids, enolates, hydrazines, dithianes etc) of alkyl halides, tosylates, mesylates and azides; ester, amide and urea formation by displacement of an activated ester or carbonate or carbamate; and aromatic nucleophilic substitution of electron deficient aromatic compounds with amines, alcohols, thiols etc.

An example of alkylation chemistry in the presence of a protein is Nguyen, R. and Huc, I., *Angew. Chem. Int. Ed.*, 40(9), 1774-6 (2001)

A generic scheme is as follows:

- 28 -




Where LG is a leaving group, and X is a nucleophilic heteroatom or carbon anion.

5

Three or Four Component Reactions


A number of multicomponent reactions proceed under mild mixed aqueous conditions and are suitable for combinatorial library design for the purposes of this invention. One example is the Ugi condensation (see Domling, A., *Current Opinion in Chemical Biology*, **6**(3), 306-313 (2002); Ugi, I., et al., *Combinatorial Chemistry*, 125-165 (1999)):



15

Also encompassed in the scope of the invention is design of combinatorial reactions in which more than one functional group can be present on any given monomer so that multimeric ligands can be assembled. In this way two or more monomers can be assembled by two or more functional group interconversions using chemistry illustrated above or other chemistry possible under mild aqueous conditions. For example, schematically:

- 29 -



in which the monomer sets containing groups M₁ and M₂ react together through one chemistry (A+B=X) to give trimeric products containing the groups M₁ and M₂, and monomer sets containing M₁, M₂ and M₃ react together through two chemistries (A+B=X and P+Q=Y) to give trimeric products containing the groups M₁ and M₂ and M₃.

Other factors which need to be considered in designing suitable combinatorial library conditions under aqueous conditions are as follows:

Solubility in water of the reacting monomers may be limiting to the efficiency of the transformations

Catalysis - Bronsted and Lewis acid catalysis and other catalysts may be used to allow a transformation to proceed in an aqueous environment [For example Lindstroem, U., *Chemical Reviews*, 102(8), 2751-2771 (2002).]

Micelles - the use of micellar catalysts to enable the use of water as a solvent [For examples see Lindstroem, U. (2002)]

Cosolvents - the use of cosolvents to enable the use of water as a solvent including, but not limited to, DMSO, polyethylene glycols, ethylene glycols, methanol, ethanol, isopropanol, acetone and acetonitrile. These cosolvents should be compatible with the protein crystal and may typically be used in an amount of up to 20% of the solvent system, which is preferred, although

- 30 -

an amount of up to 40% or higher may be possible.

Solubilisers - the use of solubilising agents to enable the use of water as a solvent in reactions of organic compounds. [For examples see Lindstroem, U., (2002)]

- 5 *Surfactants* - the use of surfactants to enable the use of water as a solvent in reactions of organic compounds. [For examples see Lindstroem, U., (2002)] These surfactants should be compatible with the protein crystal.
- 10 The above described combinatorial library synthesis and procedures can similarly be adapted for mixed aqueous solvent conditions.

In some embodiments of the present invention, it is preferred
15 that the monomers cannot substantially bind to the target protein, but that only the collection of compounds formed include compounds that show affinity for the target protein. Preferably the ratio of the K_i of the strongest binding ligand formed to the K_i of the strongest binding monomer is at least 10 to 1, more
20 preferably 100, 1000 or even 10000 to 1.

In a preferred case, it is possible that the presence of the protein crystal in the solution in which the combinatorial chemistry takes place will exert an influence on the reactions
25 occurring. If the reactions are reversible, then without wishing to be bound by theory, this would allow generation of thermodynamic products having the advantage of allowing for the 'local enrichment' of products at the protein surface leading to formation of the most potent ligand possible in the library. The
30 principles of this effect are described by Huc, I. and Nguyen, R., *Combinatorial Chemistry and High Throughput Screening*, 109-130 (2001). If the reactions are irreversible, then without wishing to be bound by theory, this would allow generation of kinetic products having the advantage of 'local templating' of
35 products at the protein surface leading to formation of the most potent ligand possible in the library. The principles of this effect are described by Nguyen, R. and Huc, I., *Angew. Chem. Int.*

- 31 -

Ed., 40(9), 1774-6 (2001) and in 'click chemistry' e.g. Lewis, W., et al., Angew. Chem. Int. Ed., 41(6), 1053-1057 (2002).

'Just-in-time' synthesis

5 As 'just-in-time' synthesis is not carried out in the presence of the protein crystals, there is less restriction on the types of chemistries that can be used to generate the collections of compounds for screening. However, in selecting appropriate starting materials and reaction conditions, it is preferred that
10 the reactions do not result in a large number of by-products that could interfere with the screening process, and so reactions that do not require extraneous reagents are preferred.

The reactions discussed above in relation to the 'in-situ'
15 synthesis would be particularly suitable, but other reactions could be considered, for example those using methodology in which the reagents that catalyse or drive the synthetic conversions are bound onto a solid phase medium and therefore removed from the solution by filtration. These chemistries, suitable for use with
20 this invention, are described by Ley, S.V., et al., Perkin I, 23, 3815-4195 (2000) and references cited therein.

Such reactions can be carried out using synthetic procedures described in general organic chemistry texts such as March's
25 Advanced Organic Chemistry (Smith, M.B. and March, J., 5th edition, Wiley-Interscience, New York, 2001) or references given therein, and reference is also made to the texts on the practice of combinatorial chemistry given above.

30 As in 'in-situ' synthesis, the reactions take place between appropriate sets of ligand precursor molecules ('monomers'), in which at least one substituent group is varied, to result in sets of monomers. Each reacting set of monomers can have as few as a single member, up to, for example, 40 members, although a maximum
35 of about 20 members would be more usual. In some embodiments of the invention it is preferred that each set of reacting monomers comprises at least two monomers. A typical size for the

- 32 -

resulting collection of compounds would be between 5 and 1000, preferably between 5 and 100, with a range 10 or 20 to 50 or 70 being preferred.

5 The usual purification and characterisation steps which are used in the practice of combinatorial or parallel synthesis are not required in methods according to the present invention. These steps are viewed as essential in the conventional practice of these synthesis methods in order to produce compounds suitable
10 for testing in a biological assay, as described in many of the references cited herein. Purification does not involve physical separation techniques such as solvent evaporation or removal of insolubles, e.g. by sedimentation, centrifugation or filtration.
15 Conventional purification methods include aqueous extraction, trituration, chromatography such as flash column chromatography or HPLC purification, crystallisation and distillation, although certain characterisation methods can also be used in purification. Characterisation may be carried out in a number of ways, including using LCMS, MS and NMR analysis.
20

In a particularly preferred embodiment of the invention, the chemistry used for the 'just-in-time' synthesis is carried out in a solvent suitable as a co-solvent for aqueous solutions of protein crystals. Such solvents include DMSO, NMP and alcohols
25 such as methanol and ethanol (for more details, see discussion of cosolvents in 'in-situ' synthesis). In this way, after incubation of the reaction for a suitable period of time, aliquots can be taken of the solution and added directly to the protein crystal containing solution, without the need for any
30 purification or characterisation steps.

Example


The protein chosen as the target macromolecule was cyclin-dependent kinase 2 (CDK2). This target has been the subject of
35 intense study with the aim of developing inhibitors for the treatment of a number of human cancers, and has been crystallized with a number of inhibitors bound in the ATP-binding groove (De

- 33 -

Azevedo, W.F., et al., *Eur. J. Biochem.*, **243**, 518-526 (1997);
 Hoessl, R., et al., *Nat. Cell Biol.*, **1**, 60-67 (1999))

The collection of compounds chosen for synthesis were based on
 5 the oxindole template, being a class of inhibitors already
 disclosed for CDK2 (Bramson, H.N., et al., *J. Med Chem.*, **44**,
 4339-4358 (2001)). These ligands (**AB**; Scheme 1) present
 substituents in adjacent lipophilic binding pockets within the
 ATP binding groove and can be disconnected to monomers of
 10 approximately equal size and complexity (hydrazines **A** and isatins
B; Scheme 1).

Scheme 1














15

A range of hydrazines (A1 to A6; Table 1) and isatins (B1 to B5; Table 1) were chosen, so that the collection of oxindoles formed would present a range of functional groups to the ATP binding site.

20

- 34 -


Table 1

Hydrazines		Isatins	
A1		B1	
A2		B2	
A3		B3	
A4		B4	
A5		B5	
A6			

The synthesis of the collection of ligands was then demonstrated to proceed under aqueous conditions in the presence of 20% of the 5 co-solvent dimethylsulfoxide (DMSO), according to scheme 2:

- 35 -

Scheme 2



Analysis by mass spectrometry of the 30 reactions in the array
 5 indicated that all reactions successfully formed the expected
 products over a 24-72 hour period and the efficiency of the
 individual reactions was assessed by LC/MS analysis (Table 2). In
 most cases, under these reaction conditions, the products slowly
 precipitated from the reaction solution over time. It is clear
 10 from the qualitative data presented in Table 2 that monomer A6
 did not give high conversions or high purity in the reactions and
 that some other individual reactions were also poor, however, the
 variability in absolute amount of products formed between
 individual reactions would be expected to be no more than 10-fold
 15 from these results.

- 36 -

Table 2 (% purity by peak area of product by LC/MS)

A X B	A1	A2 R ¹ = Cl	A3 R ² = Cl	A4 R ³ = Cl	A5 R ³ = SO ₂ NH ₂	A6 R ¹ = Cl; R ³ = SO ₂ Me
B1 R ⁵ = NO ₂	10-25	60-95	60-95	30-50	60-95	30-50
B2 R ⁵ = Cl	60-95	60-95	60-95	60-95	60-95	30-50
B3 R ⁵ = SO ₃ H	10-25	60-95	30-50	10-25	60-95	30-50
B4 R ⁷ = CF ₃	30-50	60-95	60-95	60-95	60-95	30-50
B5 R ⁵ = OCF ₃	30-50	60-95	60-95	60-95	60-95	10-25

R groups = H unless indicated otherwise.

Monomer studies to investigate kinetic competition of the monomers indicated that the products formed non-stoichiometric mixtures since it would be expected that the hydrazines and isatins would have varying reactivities. LC/MS analysis of competition experiments (using Photodiode Array Detector scanning from 200-400 nm wavelengths) indicated that mixtures of the hydrazines reacted with a 10-fold deficit of each isatin gave less than a 5-fold excess of any individual product over any other and typically less than 3-fold excess. These data again indicated that monomer A6 tended to be disfavored but again a measurable amount of product resulting from reaction of this monomer with each isatin was detected (5-10% of the mixture).

These results show that during ligand synthesis in the presence of the protein all of the reaction products were capable of being formed at a useful concentration. Additionally, under these conditions, thermodynamic products would be expected to

- 37 -

predominate because the reactions are fully reversible.

Analysis of the reactions, e.g. by LC-MS and isolation of the compounds is not required for the method of the invention, but
5 having now established reaction conditions suitable for use in the X-ray screening method disclosed in this invention, it is now possible to change the substitution patterns present in the monomer sets A and B (i.e. R¹-R⁷) and to carry out *in situ* synthesis of further libraries of compounds, not described
10 herein, in the presence of CDK2 crystals.

Crystals of full length (residues 1-298), human, cdk2 were grown. For soaking purposes crystals were transferred into a solution that maintained the ionic strength and precipitant concentrations
15 of the original crystal mother liquor, but also contained 20% DMSO and the hydrazine and isatin reactive species (see Table 3). In all cases the total hydrazine concentration was in 10-fold excess over the isatin concentration.

20 The present invention also includes the use of the aforementioned methods for the generation of CDK2 ligands.

Experimental Methods

Crystals of full length (amino acids 1-298) human cyclin
25 dependent kinase 2 (cdk2) were grown under the conditions detailed in (1) Lawrie, et al., *Nat. Str. Biol.*, **4**, 796-800 (1997) and (2) Rosenblatt, J., et al., *J. Mol. Biol.*, **230**, 1317-1319 (1993). Crystals grown using (1) were obtained using the hanging drop, vapour diffusion method, at 4°C, or 18°C. 1 µl of
30 10 mg/ml cdk2 in 10 mM Hepes/NaOH pH 7.4, 15 mM NaCl, was mixed with 1 µl of reservoir solution. The reservoir solutions (1 ml total volume) contained (25-55) mM ammonium acetate, (10-17.5)% polyethylene glycol (PEG) (average molecular weight 3350) and 100 mM HEPES/NaOH pH 7.4. Crystals grown using (2) were also
35 produced by the hanging drop, vapour diffusion, method at 4°C. 4 µl of 10 mg/ml cdk2 in 10 mM HEPES/NaOH pH7.4 were suspended over

- 38 -

a 1ml reservoir solution containing (200-800) mM HEPES/NaOH pH 7.4.

For soaking purposes crystals grown using (1) were transferred
5 into microbridges containing 20 μ l of soak solution. Soak
solutions were prepared such that the ammonium acetate, PEG and
HEPES/NaOH pH 7.4 concentrations were identical to the drop from
which a given crystal was harvested. The soak solutions further
contained 20% DMSO and the hydrazine and isatin species that were
10 to be reacted. Hydrazine and isatin concentrations in the ranges
(5-20) mM (total organic) and (0.5-2) mM (total organic)
respectively were used. Total organic refers to the fact that in
a soak solution containing multiple isatins and hydrazines the
combined concentration of all the hydrazines would be (5-20) mM
15 and the combined concentration of all the isatins would be (0.5-2
mM). All hydrazines were present in equimolar concentrations and
all isatins were present in equimolar concentrations. That is;
if a soak solution contained two isatins and four hydrazines with
total organic hydrazine and isatin concentrations of 10 mM and 1
20 mM respectively each of the isatins would be present at a
concentration of 0.5 mM and each of the hydrazines at a
concentration of 2.5 mM. Soak solutions typically contained
permutations of (1-5) isatins and/or (1-6) hydrazines (see Table
1.). The generic formula for the products formed by permuting
25 the reactants is given in Scheme 2 (see also Table 2.). The
exact nature of the products formed is detailed in Table 2.
Crystals were soaked for 3-5 days at 18°C.

Crystals were frozen by momentarily dipping them into a cryo-
30 protectant solution and then snap cooling them in liquid
nitrogen. The cryo-protectant solutions contained (17.5-22.5)%
glycerol and ammonium acetate, PEG and HEPES/NaOH pH 7.4
concentrations that were identical to the drops from which the
crystals were originally harvested.

57

Crystals grown using (2) were soaked, and frozen identically to
those grown using (1), except that rather than maintaining

- 39 -

ammonium acetate, PEG and HEPES/NaOH pH 7.4 concentrations only the HEPES/NaOH pH 7.4 concentration was maintained.

X-ray diffraction data were collected from soaked crystals,
5 cooled to 100K, on a Rigaku copper rotating anode source using
Rigaku/MSC Jupiter CCD, or Raxis IV++ image plate, detectors.
The data were integrated, reduced and scaled using either the
D*TREK suite (Pflugrath, J.W., *Acta Crystallographica*, D55, 1718-
1725 (1999)), or MOSFLM (Leslie, A.G.W. In *Joint CCP4 and EESF-*
10 *EACMB Newsletter on Protein Crystallography*, vol. 26, Warrington,
Daresbury Laboratory (1992)), SCALA and the CCP4 suite of
programs (CCP4: see above). An apo-cdk2 structure (DeBondt,
H.L., et al., *Nature*, 363, 595-602 (1993)) was used as a starting
point for structure refinements. The structures were initially
15 segmented into 25 amino acid sections and rigid-body refined in
CNX (see above). The structures were then subjected to iterative
cycles of positional and isotropic B-factor refinement in CNX ,
followed by manual rebuilding using the graphics program "O" (see
above) and automated ligand fitting using AUTOSOLVE®. Final
20 water fitting was performed using in-house software. Details of
representative X-ray data are given in Table 3.

- 40 -

Table 3. Representative X-ray results and experimental conditions

<i>Components in soaking solution</i>	A5+B2	A5+B3	A5+B5	A5+B1	B2+ (A1,A2, A3,A4)	B2+ (A1,A2, A3,A4, A5,A6)	(B1,B2,B3, B4,B5)+(A1,A2,A3, A4,A5,A6)
Space group	P2 ₁ 2 ₁ 2 ₁						
a (Å)	53.68	53.69	53.50	53.73	53.53	53.62	53.69
b (Å)	71.94	71.94	71.41	72.11	71.48	71.83	72.41
c (Å)	71.90	72.25	72.12	72.36	72.22	71.89	72.10
Maximal resolution	2.20	2.25	2.65	2.70	2.20	2.20	2.80
Observations	36740	41480	22249	23195	36709	35997	22680
Unique reflections	14265	13583	8277	8470	14171	14250	6991
Completeness (%)	97.2	98.5	98.2	98.6	92.7	89.1	96.9
R _{merge}	0.088	0.153	0.122	0.143	0.057	0.035	0.127
Mean I/σI	4.3	4.1	3.8	3.7	6.2	8.6	4.8
Highest resolution bin (Å)	2.28-2.2	2.33-2.25	2.74-2.65	2.74-2.65	2.28-2.2	2.28-2.2	2.95-2.8
Completeness (%)	88.5	97.8	99.5	100	86.8	85.2	98.0
R _{merge} ¹	0.28	0.284	0.332	0.344	0.187	0.134	0.258
Mean I/σI	2.0	2.4	2.0	2.1	2.3	3.0	2.8
Refinement							
Protein atoms	2279	2279	2279	2279	2279	2279	2279
Other atoms							
Inhibitor	23	26	27	25	0	23	23
Water	139	129	57	39	245	229	67
Resolution range (Å)	35-2.2	35-2.25	35-2.65	35-2.7	35-2.2	35-2.2	35-2.8
R _{conv} (%) ²	25.9	24.7	23.7	24.3	25.6	24.6	21.1
R _{free} (%) ³	30.6	28.9	29.0	28.1	27.2	25.5	24.9
Mean B-factor (Å ²)							
Protein	37.0	38.1	42.2	49.0	26.1	30.8	30.6
Ligand	31.2	37.3	47.0	59.7	NA	24.3	25.5
Solvent	47.2	42.8	35.5	50.4	34.2	41.5	34.8
Soaks							
Isatin conc (mM)	2 ⁶	0.5 ⁶	0.5 ⁶	1 ⁶	1	1	1 (total organic ⁴)
Hydrazine conc (mM)	20	5	5	10	10 (total organic ⁴)	10 (total organic ⁴)	10 (total organic ⁴)
Soak time (days)	5	3	3	3	3	3	3
Product present	YES ⁵	YES ⁵	YES ⁵	YES ⁵	NO ⁵	YES ⁵	YES ⁵

- 41 -

¹R_{merge} = $\Sigma_h \Sigma_j |I_{h,j} - \bar{I}_h| / \Sigma_h \Sigma_j |I_{h,j}|$, where I_{h,j} is the jth observation of reflection h.

²R_{conv} = $\Sigma_h ||F_o| - |F_c|| / \Sigma_h |F_o|$, where F_o and F_c are the observed and calculated structure factor amplitudes respectively for the reflection h.

³R_{free} is equivalent to R_{conv}, but for a 5% subset of the reflections not used for refinement.

⁴ total organic refers to the total combined isatin, or hydrazine, concentration in the soak. Each component being present at a concentration equal to the total organic concentration divided by the number of isatin, or hydrazine, components in the mix.

⁵Control experiments with crystals soaked for (3-5) days in cocktails containing either B2(20 mM), (B1,B2,B3,B4,B5) (1mM total organic⁴), or (A1,A2,A3,A4,A5,A6) (1 mM total organic) did not reveal any interpretable ligand density. Crystals soaked in a 10 mM cocktail of (A1,A2,A3,A4,A5,A6) were repeatedly destroyed.

⁶In certain instances it was found that crystals subjected to soaks that contained only one hydrazine and one isatin sustained increased damage as compared to those soaked in multi-component isatin-hydrazine cocktails. Isatin and hydrazine concentrations were iteratively reduced until soaking crystals could be stabilised, and crystal damage diminished. Precipitation, attributed to isatin-hydrazine product formation, was frequently observed during soaks.

25

Discussion of Results

Initial experiments were performed using reaction cocktails that contained a single isatin and a single hydrazine. In these instances, product binding was observed. Previous studies (Bramson, H.N., et al., *J. Med Chem.*, 44, 4339-4358 (2001)) suggested that inhibitors derived from A5 (see Fig 1 & Table 2) should possess a relatively high degree of potency due to the presence of the sulphonamide group at the R³ position in the ligand. A reaction cocktail containing B2 and (A1-A4) did not reveal ligand binding, suggesting that the chlorine substitutions at positions (R¹-R³) did not confer significant potency upon the product ligands. A cocktail that contained B2+(A1-A6) did,

- 42 -

however, reveal ligand binding; the electron density being consistent with product formed by the reaction of (B2+A5). Thus the (B2+A5) reaction product was preferentially selected from a set of six possible products, lending support to the notion that 5 the R³-sulphonamide group was conferring binding affinity upon the A5B2 ligand. The degeneracy of the product library was increased to 30 possible ligands using a reaction cocktail that contained isatins (B1-B5) and hydrazines (A1-A6). Each isatin was present at a concentration of 0.2 mM and each hydrazine at a 10 concentration of 1.67 mM (see Table 3). Difference electron density consistent with the reaction product from (B2+A5) was again observed. These studies suggest that the protein preferentially selects the A5B2 ligand from the library of available product ligands. The potency of this compound was 15 confirmed by synthesis of A5B2 ligand. It is known from the literature that compound A5B2 has an IC50 of 43 nM (Bramson, et al., 2001).

Claims

1. A method for identifying a ligand of a target macromolecule
5 comprising the steps of:

- a) soaking one or more crystals of the target macromolecule in a solution containing a collection of compounds generated in situ or separate from the crystal, where the solution has been prepared without the purification of
10 the synthesized collection of compounds;
- b) obtaining an X-ray crystal diffraction pattern of the soaked macromolecule crystal; and
- c) using said X-ray crystal diffraction pattern to identify any compound bound to the macromolecule crystal, said
15 compound being a ligand of the target macromolecule.

2. A method for identifying a ligand of a target macromolecule comprising the steps of:

- a) synthesizing a collection of compounds, which are suitable for screening against a target macromolecule, in a solution containing one or more crystals of the target macromolecule;
- b) obtaining an X-ray crystal diffraction pattern of the soaked macromolecule crystal; and
- c) using said X-ray crystal diffraction pattern to identify any compound bound to the macromolecule crystal, said
25 compound being a ligand of the target macromolecule.

3. A method for identifying a ligand of a target macromolecule
30 comprising the steps of:

- a) synthesizing a collection of unpurified compounds, which are suitable for screening against a target macromolecule;
- b) adding the collection of compounds to a solution containing one or more crystals of the target macromolecule;
- c) obtaining an X-ray crystal diffraction pattern of the
35

- 44 -

soaked macromolecule crystal; and

- d) using said X-ray crystal diffraction pattern to identify any compound bound to the macromolecule crystal, said compound being a ligand of the target macromolecule.

5

4. A method according to claim 3, wherein if step a) takes place in a solvent which is not compatible with the macromolecule crystals, then the method comprises the further step after step a) of separating the collection of compounds from the solvent in 10 which the compounds were synthesised.

5. A method according to claim 3, wherein if step a) takes place in a solvent which is not compatible with the macromolecule crystals, the solvent in which step a) takes place is separated 15 from the solution containing the one or more macromolecule crystals by a permeable membrane.

6. A method according to any one of claims 1 to 5, wherein the target macromolecule is selected from the group consisting of: 20 proteins, ribose nucleic acids, deoxy ribose nucleic acid, and complexes of combinations of these.

7. A method according to claim 6, wherein the target 25 macromolecule is a protein.

8. A method according to any one of claims 1 to 7, wherein the collection of compounds are synthesised individually and then mixed together.

30 9. A method according to any one of claims 1 to 7, wherein the collection of compounds are synthesised as a mixture by combinatorial chemistry.

35 10. A method according to any one of claims 1 to 9, wherein the members of the collection of compounds are present at a concentration of at least 10 times their K_i .

- 45 -

11. A method according to any one of claims 1 to 10, wherein the amount of each compound being a member of the collection of compounds, present in the solution will be present at a concentration which is at least 10 times as much as the
5 concentration of the target macromolecule in the reaction system.

12. A method according to any one of claims 1 to 11, wherein the members of the collection of compounds do not bind covalently to the target macromolecule.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 03/05595

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, INSPEC, COMPENDEX, BIOSIS, MEDLINE, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CARR ROBIN ET AL: "Structure-based screening of low-affinity compounds." DRUG DISCOVERY TODAY, vol. 7, no. 9, 1 May 2002 (2002-05-01), pages 522-527, XP002279162 ISSN: 1359-6446 (ISSN print) the whole document page 525, right-hand column, line 3 -page 526, left-hand column, line 5 ---	1-12
A	WO 99/45379 A (ABBOTT LAB) 10 September 1999 (1999-09-10) cited in the application the whole document ---	1-12

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the International search

6 May 2004

Date of mailing of the International search report

21 APR 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Tuynman, A

INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 03/05595	
---	--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EKSTEROWICZ J E ET AL: "Coupling structure-based design with combinatorial chemistry: application of active site derived pharmacophores with informative library design" JOURNAL OF MOLECULAR GRAPHICS & MODELLING, JUNE 2002, ELSEVIER, USA, vol. 20, no. 6, pages 469-477, XP002275868 ISSN: 1093-3263 the whole document</p> <p>---</p>	1-12
A	<p>LEWIS W G ET AL: "Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks" ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 41, no. 6, 2002, pages 1053-1057, XP002967538 ISSN: 0570-0833 cited in the application the whole document</p> <p>---</p>	1-12
A	<p>NGUYEN R ET AL: "Using an Enzyme's Active Site To Template Inhibitors" ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 40, no. 9, 2001, pages 1774-1776, XP002275869 cited in the application the whole document</p> <p>---</p>	1-12
P,X	<p>CONGREVE MILES S ET AL: "Detection of ligands from a dynamic combinatorial library by X-ray crystallography." ANGEWANDTE CHEMIE (INTERNATIONAL ED. IN ENGLISH) GERMANY 29 SEP 2003, vol. 42, no. 37, 29 September 2003 (2003-09-29), pages 4479-4482, XP002275867 ISSN: 0570-0833 the whole document</p> <p>-----</p>	1-12

INTERNATIONAL SEARCH REPORT

 International Application No
PCT/GB 03/05595

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9945379	A	10-09-1999	AU 2887099 A	20-09-1999
			AU 767991 B2	27-11-2003
			AU 2987899 A	20-09-1999
			BG 104802 A	30-04-2001
			BR 9908563 A	21-11-2000
			CA 2321968 A1	10-09-1999
			CN 1299467 T	13-06-2001
			EP 1068531 A2	17-01-2001
			HU 0101959 A2	28-09-2001
			JP 2002506206 T	26-02-2002
			NO 20004433 A	06-11-2000
			PL 343264 A1	30-07-2001
			SK 13242000 A3	12-03-2001
			TR 200002572 T2	21-11-2000
			TR 200101127 T2	21-06-2002
			TR 200101129 T2	21-06-2002
			TR 200101200 T2	21-02-2002
			WO 9945389 A2	10-09-1999
			WO 9945379 A2	10-09-1999
			US 6297021 B1	02-10-2001